While M2-targeted therapeutic strategies may be appropriate for acute leukemias, lymphomas, and MM where M2 macrophages drive pathology, our findings suggest that therapeutic approaches targeting the inflammatory axis may be more relevant in JAK2-positive MPNs [4]. The gene discussed is JAK2; the disease is lymphoma.